We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-5.41%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$7.1B
AUM Growth
-$1.16B
Cap. Flow
-$291M
Cap. Flow %
-4.1%
Top 10 Hldgs %
41.94%
Holding
104
New
17
Increased
24
Reduced
34
Closed
18
Avg Time Held
5.6 quarters
Top 10 Avg Time Held
6.9 quarters
Top 20 Avg Time Held
4.2 quarters

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$151M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$136M
3
MDT icon
Medtronic
MDT
+$115M
4
DXCM icon
DexCom
DXCM
+$83.5M
5
LIVN icon
LivaNova
LIVN
+$79.9M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$149M
2
GILD icon
Gilead Sciences
GILD
+$133M
3
ONEM
1Life Healthcare
ONEM
+$129M
4
BEAM icon
Beam Therapeutics
BEAM
+$119M
5
SNY icon
Sanofi
SNY
+$96.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.86%
2 Financials 0.83%
3 Consumer Staples 0.3%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
FATE icon
1
Fate Therapeutics
FATE
$246M
$1.07B 15.05%
12,957,222
+327,485
+3% +$31.4M
2015 Q2
23 quarters
ALLK icon
2
DELISTED
Allakos
ALLK
$278M 3.91%
2,419,418
-248,033
-9% -$31.3M
2018 Q3
10 quarters
IGMS icon
3
DELISTED
IGM Biosciences
IGMS
$263M 3.7%
3,425,455
– –
2019 Q3
6 quarters
ARGX icon
4
argenx
ARGX
$50.6B
$234M 3.3%
849,845
-68,462
-7% -$21.6M
2017 Q4
13 quarters
FOLD icon
5
DELISTED
Amicus Therapeutics
FOLD
$209M 2.94%
21,114,114
+493,624
+2% +$7.64M
2013 Q2
31 quarters
BEAM icon
6
Beam Therapeutics
BEAM
$2.52B
$203M 2.86%
2,532,523
-1,245,739
-33% -$119M
2020 Q1
4 quarters
DCPH icon
7
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$195M 2.75%
4,351,644
-86,324
-2% -$4.02M
2017 Q3
14 quarters
NVTA
8
DELISTED
Invitae Corporation
NVTA
$185M 2.61%
4,852,163
-411,146
-8% -$18.7M
2020 Q2
3 quarters
ADCT icon
9
ADC Therapeutics
ADCT
$214M
$178M 2.51%
7,308,418
+549,624
+8% +$15.9M
2020 Q2
3 quarters
STTK icon
10
Shattuck Labs
STTK
$584M
$164M 2.31%
5,619,914
– –
2020 Q4
1 quarter
MDVL
11
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$164M 2.31%
234,495
– –
2020 Q4
1 quarter
OSH
12
DELISTED
Oak Street Health, Inc.
OSH
$159M 2.24%
2,930,411
+4,700
+0.2% +$261K
2020 Q3
2 quarters
KRYS icon
13
Krystal Biotech
KRYS
$9.53B
$159M 2.24%
2,060,132
+385,096
+23% +$28M
2018 Q4
9 quarters
JAZZ icon
14
Jazz Pharmaceuticals
JAZZ
$13.8B
$136M 1.92%
+829,159
New +$136M
2021 Q1
0 quarters
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
$130M 1.83%
+937,045
New +$151M
2021 Q1
0 quarters
PLRX icon
16
Pliant Therapeutics
PLRX
$60.7M
$126M 1.78%
3,207,193
-181,183
-5% -$5.88M
2020 Q2
3 quarters
REPL icon
17
Replimune Group
REPL
$1.16B
$126M 1.77%
4,118,212
+124,813
+3% +$4.67M
2018 Q3
10 quarters
MDT icon
18
Medtronic
MDT
$117B
$116M 1.63%
+979,108
New +$115M
2021 Q1
0 quarters
SRRK icon
19
Scholar Rock
SRRK
$4.97B
$110M 1.55%
2,176,628
-719,961
-25% -$39.8M
2018 Q2
11 quarters
NRIX icon
20
Nurix Therapeutics
NRIX
$2.32B
$103M 1.45%
3,314,117
+467,992
+16% +$17.7M
2020 Q3
2 quarters
KYMR icon
21
Kymera Therapeutics
KYMR
$9.13B
$101M 1.42%
2,603,139
-117,350
-4% -$7.06M
2020 Q3
2 quarters
ATRA icon
22
Atara Biotherapeutics
ATRA
$88.4M
$98.9M 1.39%
275,409
+886
+0.3% +$392K
2014 Q4
25 quarters
STOK icon
23
Stoke Therapeutics
STOK
$1.48B
$98.8M 1.39%
2,544,062
-142,172
-5% -$8.09M
2019 Q2
7 quarters
ZNTL icon
24
Zentalis Pharmaceuticals
ZNTL
$232M
$96.4M 1.36%
2,221,044
-195,362
-8% -$8.41M
2020 Q2
3 quarters
ANNX icon
25
Annexon
ANNX
$726M
$96.3M 1.36%
3,458,830
+10,800
+0.3% +$297K
2020 Q3
2 quarters
1
2 3 4 5

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2021 Portfolio in Review

As of Q1 2021, Redmile Group held 104 positions worth $7.1B, down 14% from $8.26B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group withdrew a net $291M in Q1 2021, closing 18 positions and reducing 34 holdings. Its most notable exit was AbbVie, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Redmile Group opened a new position in Seagen Inc. Common Stock worth $130M.

  • Redmile Group's largest Q1 2021 buy was Seagen Inc. Common Stock: 937,045 shares worth $130M.
  • Redmile Group added most to Fate Therapeutics in Q1 2021, an estimated $31.4M increase.
  • Redmile Group's biggest Q1 2021 reduction was 1Life Healthcare, cutting an estimated $129M.
  • Redmile Group fully exited AbbVie in Q1 2021, selling an estimated $149M.
  • Redmile Group's ten largest holdings make up 42% of its $7.1B portfolio in Q1 2021.
  • Redmile Group opened 17 new positions and closed 18 in Q1 2021.
  • Redmile Group's portfolio value fell 14% quarter-over-quarter to $7.1B.

Based on Redmile Group's 13F filing for Q1 2021, filed 17 May 2021.